Navigation Links
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
Date:5/9/2013

R-181: Implications for Labeling", Webster, L., et al. 
  • Date: June 20, 2013, 7:30 a.m. – 9:30 a.m. Pacific Time
  • Poster 1598130: "Opioids With Lower Brain Uptake Are Less Recognizable in Rat Drug Discrimination Tests and thus Potentially Less Subject to Abuse", Harrison, S., et al. 
  • Date: June 19, 2013, 12:00 p.m. – 2:00 p.m. Pacific Time
  • Conference Call to Discuss First Quarter 2013 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time today, Thursday, May 9, 2013.

    This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, June 10, 2013. To access the conference call, follow these instructions:Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)Passcode: 36590300 (Nektar Therapeutics is the host)In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

    About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily
    '/>"/>

    SOURCE Nektar Therapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
    2. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
    3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
    5. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
    6. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
    7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
    8. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
    9. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
    10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
    11. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... JERUSALEM , August 19, 2014 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Intellectual Property Department of ... patent for its invention, titled "Methods and Compositions ... Oramed Pharmaceuticals  Oramed Pharmaceuticals is a ...
    (Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 /PRNewswire/ ... announced today a protocol amendment to allow for expanded dosing ... U.S. Food and Drug Administration (FDA) and that a new ... at three clinical trial sites in the United ... of US$2.9 million have been raised through warrant exercise in ...
    (Date:8/19/2014)... ,Weight Loss- Market Analysis, Global API Manufacturers ... insights about phase III pipeline drugs and marketed drugs ... is to establish the understanding for API Manufacturers for ... countries and regions. While the leading brands, companies and ... on the drug master filings across the US, ...
    Breaking Medicine Technology:Oramed Granted Patent in Spain for Oral Administration of Insulin 2Oramed Granted Patent in Spain for Oral Administration of Insulin 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4
    ... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),a Xianyang-based developer, manufacturer ... announced financial results the third quarter ended September 30, 2009. , , ... ... Q3 2008 ...
    ... TRIANGLE PARK, N.C., Nov. 12 Chimerix, Inc., ... address life-threatening diseases, announced today that Kenneth I. ... overview at two upcoming investor conferences. Mr. ... pipeline, including CMX001, a broad-spectrum antiviral being developed ...
    Cached Medicine Technology:Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 2Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 3Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 4Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 5Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 6Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 7Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 8Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 9Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 10Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 11Chimerix to Present at Two Upcoming Investor Conferences 2
    (Date:8/20/2014)... 20, 2014 No matter how “lonely” a ... a steady set of friends to be always there for ... to the concept of making new friends during adulthood ... ranging from taking care of one’s family to a near-slavish ... to a new person just is not the same as ...
    (Date:8/20/2014)... Springs, California (PRWEB) August 20, 2014 ... , designed the innovative RevitaDERM® Psoriasis Treatment ... that is associated with psoriasis. This all-in-one product ... symptoms. , RevitaDERM® Psoriasis Treatment is powered by ... odor commonly associated with this effective ingredient. ...
    (Date:8/20/2014)... First Choice Emergency Room , ... the United States, named Richard Daniels, DO the Medical ... , “We are pleased to announce that Dr. ... second facility in Pflugerville,” said Dr. James M. Muzzarelli, ... , Dr. Daniels received his undergraduate degree from Brigham ...
    (Date:8/20/2014)... What to Do Now for UDI:, ... the Market, **FDAnews Webinar**, Sept. 11, 2014 — 1:30 ... Hospitals and other buyers of devices lose $5 billion ... systems. , Complying with the FDA’s deadlines is important, ... UDI as soon as possible. If devicemakers don’t, ...
    (Date:8/19/2014)... As moms and dads prepare their children ... to the normal routine of dropping their little ones off ... MSc, RD encourages them to use the opportunity to ... , Yarker explains, “Kids have small tummies, short attention ... them junk food handouts, use snack time as another daily ...
    Breaking Medicine News(10 mins):Health News:‘How to Make Friends as an Adult by Just Being Yourself: Becoming a “People Person” In Three Steps or Less’ Gives Tips for Making Friends During Adulthood - Vinamy 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 2Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 3Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 4Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
    ... TSTF ), a national provider of healthcare ... for the quarter,ended September 30, 2007. TeamStaff,s revenues ... 30, 2007 were $16.5 million as,compared to $ ... Income from,operations for the three months ended September ...
    ... BRIGHTON, Mich., Jan. 15 Denise ... the nationally,recognized addiction treatment facility has formed ... mission of this newly created, IRS,approved foundation ... by fund,raising to support the highest standards ...
    ... only a few have actually owned up for the record ... doctors say they are willing to report medical errors, but ... finds. , "The most important message seems to be that ... to improve performance over time and reporting of errors," said ...
    ... D.C. − Researchers at Lombardi Comprehensive Cancer Center at ... known as cyclin D1 may be the Achilles heel ... − which is the most common type of breast ... of the journal Oncogene, investigators say the findings support ...
    ... January 15, 2008 - Wiley-Blackwell, the scientific, ... John Wiley & Sons, Inc (NYSE: JWa), ... Collaboration, the not-for-profit organisation dedicated to improving ... publish The Cochrane Library. , The Cochrane ...
    ... Company to Immediately Address FDA Ruling, TORONTO, ... (TSX: PMD; Amex: PME) announced today that it ... U.S. Food and Drug,Administration (FDA) regarding the 510(k) ... (POC) skin cholesterol test. The,company expects to evaluate ...
    Cached Medicine News:Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 2Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 3Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 4Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 5Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 6Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 7Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 8Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 9Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 10Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 11Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 12Health News:TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations 13Health News:Brighton Hospital Announces Creation of Brighton National Addiction Foundation 2Health News:Study Finds Doctors Not Reporting Medical Mistakes 2Health News:Study Finds Doctors Not Reporting Medical Mistakes 3Health News:Findings point to molecular 'Achilles heel' for half of breast cancer tumors 2Health News:Findings point to molecular 'Achilles heel' for half of breast cancer tumors 3Health News:PreMD Announces FDA Decision on POC Skin Cholesterol Test 2Health News:PreMD Announces FDA Decision on POC Skin Cholesterol Test 3
    ... ECG Systems offer clinical features to meet ... functionality for paperless storage. Flexible, affordable, and ... PCE Exercise ECG software turns any computer ... with its ability to connect with leading ...
    ... CardioDirect12-S is the stress testing system from ... turn-key system including treadmill or bicycle ergometer, ... BP option. It uses the same CardioDirect ... resting ECG. ,The system is ...
    ... Burdick ExTOL systems feature your choice ... multi-channel electrocardiographs, an easy-to-operate monitor and ... ExTOL exercise stress testing systems also ... measurement point, pre-programmed or custom protocols, ...
    The Urchin heart positioner provides excellent access to target coronaries while minimizing hemodynamic instability...
    Medicine Products: